Soluble guanylyl cyclase: A novel target for the treatment of vascular cognitive impairment?
Pharmacological Research, 2023 Vascular cognitive impairment (VCI) describes neurodegenerative disorders characterized by a vascular component. Pathologically, it involves decreased cerebral blood flow (CBF), white matter lesions, endothelial dysfunction, and blood-brain barrier (BBB)
Ellis Nelissen +7 more
doaj +2 more sources
Molsidomine provides neuroprotection against vincristine-induced peripheral neurotoxicity through soluble guanylyl cyclase activation [PDF]
Scientific ReportsPeripheral neurotoxicity is a dose-limiting adverse reaction of primary frontline chemotherapeutic agents, including vincristine. Neuropathy can be so disabling that patients drop out of potentially curative therapy, negatively impacting cancer prognosis.
Irina Utkina-Sosunova +15 more
doaj +2 more sources
NF-κB-responsive miR-155 induces functional impairment of vascular smooth muscle cells by downregulating soluble guanylyl cyclase [PDF]
Experimental and Molecular Medicine, 2019 Vascular disease: Small RNA as a possible culprit The overexpression of a microRNA molecule adversely affects the functioning of vascular smooth muscle cells (VSMCs) and may contribute to the development of artherosclerosis and preeclampsia.
Minsik Park +14 more
doaj +2 more sources
Acrylamide Analog as a Novel Nitric Oxide-Independent Soluble Guanylyl Cyclase Activator
Journal of Pharmacological Sciences, 2006 Soluble guanylyl cyclase (sGC) is a target enzyme for endogenous nitric oxide (NO), and it converts GTP to cyclic GMP (guanosine 3’,5’-cyclic monophosphate) as part of a cascade that results in physiological processes such as smooth muscle relaxation ...
Masaki Nakane +5 more
doaj +3 more sources
Design, synthesis and biological evaluation of new 3,4-dihydroquinoxalin-2(1H)-one derivatives as soluble guanylyl cyclase (sGC) activators [PDF]
Heliyon, 2022 Herein, we present the structure-based design, synthesis and biological evaluation of novel mono- and di-carboxylic 3,4-dihydroquinoxalin-2(1H)-one derivatives as potential heme-independent activators of soluble guanylate cyclase (sGC).
Dionysios-Panagiotis Kintos +8 more
doaj +2 more sources
Hypertension reduces soluble guanylyl cyclase expression in the mouse aorta via the Notch signaling pathway [PDF]
Scientific Reports, 2017 Hypertension is a dominating risk factor for cardiovascular disease. To characterize the genomic response to hypertension, we administered vehicle or angiotensin II to mice and performed gene expression analyses.
Catarina Rippe +7 more
doaj +2 more sources
Nephroprotective effects of the soluble guanylyl cyclase stimulator, riociguat in doxorubicin-induced acute kidney injury in rats [PDF]
Toxicology ReportsThis study aimed to investigate the potential protective effects of riociguat, a soluble guanylyl cyclase (sGC) stimulator, on kidney function and structure in rats with acute kidney injury (AKI) induced by the chemotherapeutic drug doxorubicin (DX ...
Raya Al-Maskari +4 more
doaj +2 more sources
Inactivation of soluble guanylyl cyclase in living cells proceeds without loss of haem and involves heterodimer dissociation as a common step [PDF]
Br J Pharmacol, 2021 Yue Dai, Dennis J. Stuehr
openalex +2 more sources
Age Impairs Soluble Guanylyl Cyclase Function in Mouse Mesenteric Arteries [PDF]
Int J Mol Sci, 2021 Cheng Zhong +11 more
openalex +2 more sources
GAPDH delivers heme to soluble guanylyl cyclase. [PDF]
J Biol Chem, 2020 Soluble guanylyl cyclase (sGC) is a key component of NO-cGMP signaling in mammals. Although heme must bind in the sGC β1 subunit (sGCβ) for sGC to function, how heme is delivered to sGCβ remains unknown. Given that GAPDH displays properties of a heme chaperone for inducible NO synthase, here we investigated whether heme delivery to apo-sGCβ involves ...
Dai Y +4 more
europepmc +4 more sources